Immunalysis PCP Urine Enzyme Immunoassay, Immunalysis Multi-Drug Calibrators

K152176 · Immunalysis Corporation · LCM · Sep 4, 2015 · TX

Device Facts

Record IDK152176
Device NameImmunalysis PCP Urine Enzyme Immunoassay, Immunalysis Multi-Drug Calibrators
ApplicantImmunalysis Corporation
Product CodeLCM · TX
Decision DateSep 4, 2015
DecisionSESE
Submission TypeTraditional
Device ClassClass U
AttributesReal-World Evidence

Real-World Evidence

SubmissionDeviceSponsorRWD SourcesRWE Use SummaryKey Tags
K152176 · Sep 4, 2015Immunalysis PCP Urine Enzyme Immunoassay, Immunalysis Multi-Drug CalibratorsImmunalysis CorporationDiscarded clinical urine samples from clinical testing laboratoriesClinical urine samples were used to perform a method comparison study to verify the performance of the Immunalysis PCP Urine Enzyme Immunoassay against LC/MS confirmation.Method comparison; Clinical urine samples; Discarded samples

Clinical Evidence

Study DesignPopulationComparatorKey Endpoints
Method comparison study using clinical samplesUnaltered, anonymous and discarded clinical urine samples; Sample Size: 80LC/MS (Liquid Chromatography Tandem Mass Spectrometry)Qualitative and semi-quantitative assay performance (agreement)

Indications for Use

The Immunalysis PCP Urine Enzyme Immunoassay is a homogeneous enzyme immunoassay with a cutoff of 25ng/mL. The assay is intended for use in laboratories for the qualitative and semi-quantitative analysis of PCP in human urine with automated clinical chemistry analyzers. This assay is calibrated against PCP. This in-vitro diagnostic device is for prescription use only. The semi-quantitative mode is for purposes of enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as Gas Chromatography/ Mass Spectrometry (GC-MS) or permitting laboratories to establish quality control procedures. The Immunalysis PCP Urine Enzyme Immunoassay Kit provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC-MS or Liquid Chromatography/Mass Spectrometry (LC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. The Immunalysis Multi-Drug Calibrators are intended for in vitro diagnostic use for the calibration of assays for the analytes currently listed in the package insert: Benzoylecgonine, Morphine and PCP. The calibrators are designed for prescription use with immunoassays.

Device Story

Device is a homogeneous enzyme immunoassay for PCP detection in human urine. Input: human urine samples. Principle: competitive binding between drug in sample and enzyme-labeled drug conjugate for recombinant PCP antibodies; enzyme activity (G6PDH) measured via clinical chemistry analyzer. Output: qualitative (positive/negative at 25ng/mL cutoff) or semi-quantitative results. Used in clinical laboratories by technicians/scientists. Output used by clinicians to identify potential drug presence, requiring confirmation by GC-MS or LC/MS. Benefits: rapid preliminary screening for PCP abuse.

Clinical Evidence

Bench testing only. Precision study (N=80) at ±25%, ±50%, ±75%, ±100% of cutoff. Specificity/cross-reactivity tested against structurally similar and non-similar compounds. Interference tested for endogenous compounds, pH, specific gravity, and boric acid. Linearity/recovery verified. Method comparison against LC/MS (N=80) showed 100% agreement for both qualitative and semi-quantitative modes.

Technological Characteristics

Homogeneous enzyme immunoassay. Reagents: recombinant PCP antibodies, G6P, NAD, and PCP-derivative labeled with G6PDH in Tris buffer with sodium azide. Calibrators: liquid, ready-to-use synthetic urine matrix. Analyzers: automated clinical chemistry (e.g., Beckman Coulter AU 400e). Storage: 2-8°C.

Indications for Use

Indicated for qualitative and semi-quantitative analysis of PCP in human urine. Intended for laboratory use with automated clinical chemistry analyzers. Prescription use only.

Submission Summary (Full Text)

{0} # 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION ## TRIAGE-QUICK REVIEW DECISION SUMMARY 510(k) #: k152176 This 510(k) was reviewed under OIR’s Triage-Quick Review Program. This program represents an internal workload management tool intended to reduce internal FDA review resources for 510(k) applications that are of good quality upon receipt by FDA. The information in the 510(k) is complete and supports a substantial equivalence (SE) determination. Please refer to the applicant’s 510(k) summary for a summary of the information that supports this SE determination.
Innolitics

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...